Bio Medica Laboratories (NSE:BMLL) EPS without NRI: ₹ (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BMLL Bio Medica Laboratories Ltd NSE:BMLL
18 GF Score
Price ₹146.80
! 7 Warning Signs
View Full Analysis

What is Bio Medica Laboratories EPS without NRI?

Bio Medica Laboratories NSE:BMLL +1.21% 18 EPS without NRI is ₹ as of Mar. 2025. GuruFocus rates NSE:BMLL with a GF Score™ of 18/100. The stock has 7 warning signs investors should review. Among 658 Medical Devices & Instruments companies, Bio Medica Laboratories ranks worse than 151975.53% on this metric.

Bio Medica Laboratories's earnings per share without non-recurring items for the six months ended in Mar. 2025 was ₹7.79.

During the past 12 months, Bio Medica Laboratories's average earnings per share (NRI) Growth Rate was 292.00% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Bio Medica Laboratories's EPS without NRI or its related term are showing as below:

NSE:BMLL's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 8.05
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Bio Medica Laboratories's EPS (Diluted) for the six months ended in Mar. 2025 was ₹7.79.

Bio Medica Laboratories's EPS (Basic) for the six months ended in Mar. 2025 was ₹7.79.


Bio Medica Laboratories  (NSE:BMLL) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Bio Medica Laboratories EPS without NRI Related Terms


Bio Medica Laboratories EPS without NRI Historical Data

* Premium members only.

The historical data trend for Bio Medica Laboratories's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio Medica Laboratories EPS without NRI Chart

Bio Medica Laboratories Annual Data
Trend Mar23 Mar24 Mar25
EPS without NRI
0.27 1.99 7.79

Bio Medica Laboratories Semi-Annual Data
Mar23 Mar24 Mar25
EPS without NRI 0.27 1.99 7.79

NSE:BMLL vs ISRG, BDX, MDLN: EPS without NRI Comparison

For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio Medica Laboratories PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Bio Medica Laboratories's PE Ratio without NRI falls into.


NSE:BMLL
18GF Score
Bio Medica Laboratories Ltd NSE:BMLL
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio Medica Laboratories EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was ₹

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of ₹ mean?
Bio Medica Laboratories (NSE:BMLL) has a EPS without NRI of ₹ as of Mar. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Bio Medica Laboratories and its competitors. According to the industry distribution chart, Bio Medica Laboratories ranks #999999 out of 658 companies in the Medical Devices & Instruments industry.
Is Bio Medica Laboratories' EPS without NRI too high?
Bio Medica Laboratories' current EPS without NRI is ₹. Based on the distribution chart, Bio Medica Laboratories ranks #999999 out of 658 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio Medica Laboratories has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' EPS without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio Medica Laboratories ranks #999999 out of 658 companies for EPS without NRI. This places Bio Medica Laboratories in the lower half of its industry. The industry median EPS without NRI is 8.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.05, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Bio Medica Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current EPS without NRI is ₹. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current EPS without NRI of ₹. The current EPS without NRI is ₹. Bio Medica Laboratories' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current EPS without NRI is ₹ as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio Medica Laboratories Business Description

Address Sanwer Road, Plot No. 11B-11C, Sector-E, Industrial Area, Industrial Estate - Indore, Indore, MP, IND, 452015
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
18GF Score

Get the complete analysis for NSE:BMLL

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹146.80
Price